BeyondSpring (NASDAQ:BYSI) Share Price Crosses Below 50 Day Moving Average – Should You Sell?

Posted by Paula Ricardo on May 22nd, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.61 and traded as low as $1.29. BeyondSpring shares last traded at $1.44, with a volume of 23,219 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Research Report on BeyondSpring

BeyondSpring Trading Up 9.0%

The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.68. The stock has a market capitalization of $64.56 million, a P/E ratio of -11.21 and a beta of 0.41.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp bought a new position in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is currently owned by institutional investors.

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.